Plain-English translation of NCT04702256 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether obinutuzumab, a newer antibody medication, can replace high-dose oral steroids in treating lupus nephritis (kidney inflammation from lupus). Right now, doctors use oral steroids to treat this condition, but they can cause significant side effects with long-term use. This study will compare patients who receive obinutuzumab plus another drug called MMF against patients who receive traditional oral steroids plus MMF, to see if the medication works just as well while reducing steroid exposure.
Lupus nephritis damages the kidneys and is difficult to treat. While oral steroids are currently the standard treatment, long-term use causes serious side effects like weight gain, bone loss, and infections. Early evidence suggests this medication might work as well as steroids without these harmful effects — but doctors need to confirm this with a large, rigorous study before changing how they treat patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new antibody treatment or standard oral steroids, both combined with another medication called MMF. You will visit the clinic at 15 days, 1 month, 3 months, 6 months, 9 months, and 12 months for check-ups, blood tests, and urine tests to monitor your kidney function and disease activity. The study also asks you to consent to long-term follow-up at 18 months, 2 years, 5 years, and 10 years to track how well your kidneys do over time.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
France